Recursion Pharmaceuticals, INC.: management transactions · United States · SEC (Form 4)

About Recursion Pharmaceuticals, INC.

Recursion Pharmaceuticals, Inc. (ticker RXRX) is a U.S.-based biotechnology company listed on the NASDAQ in the United States, with a business model that sits at the intersection of healthcare, chemistry, and artificial intelligence. Founded in 2013, the company was built around a clear thesis: industrialize drug discovery by combining biology, automation, large-scale data generation, and advanced computing. Its corporate headquarters are in Salt Lake City, Utah, and its operating footprint extends beyond the U.S. to the United Kingdom and multiple North American talent hubs, underscoring a more international operating profile. ([recursion.com](https://www.recursion.com/our-story?utm_source=openai)) The company’s core asset is Recursion OS, a proprietary end-to-end discovery and development platform that links biological and chemical data generation with machine learning, software engineering, and experimental execution. This platform supports both the internal pipeline and selective partnerships with major pharmaceutical and technology companies. Recursion focuses on areas with substantial unmet medical need, including oncology, rare disease, neuroscience, and immunology/inflammation. The company describes itself as a “clinical stage TechBio” company, which captures its hybrid identity as both a biotech developer and a technology platform provider. ([ir.recursion.com](https://ir.recursion.com/investor-relations?utm_source=openai)) From a competitive standpoint, Recursion stands out less for a marketed product and more for a differentiated R&D engine aimed at improving speed, scale, and productivity in drug discovery. Its edge comes from generating proprietary datasets and using them to improve target selection, molecule optimization, and program prioritization. The company is pursuing potentially first-in-class and best-in-class assets while also monetizing parts of the platform through collaborations. In an industry defined by high attrition, this approach is intended to shorten timelines and lower discovery costs. ([fintel.io](https://fintel.io/doc/sec-recursion-pharmaceuticals-inc-1601830-10k-2025-february-28-20147-8813?utm_source=openai)) A major recent milestone was the completion of the combination with Exscientia in November 2024, creating a more integrated AI-driven drug discovery platform. Management stated that the combined portfolio included more than 10 clinical and preclinical programs, more than 10 advanced discovery programs, and additional partnered programs. During 2025, Recursion also reported progress in its Sanofi collaboration and announced the acquisition of Rallybio’s remaining interest in an ENPP1 program, reinforcing a strategy centered on partnership expansion, portfolio deepening, and value creation through platform leverage. ([ir.recursion.com](https://ir.recursion.com/news-releases/news-release-details/recursion-and-exscientia-two-leaders-ai-drug-discovery-space?t=&utm_source=openai))